BiomX Inc. has presented a corporate update highlighting its clinical-stage programs aimed at addressing the pressing issue of antibiotic resistance. The company focuses on phage therapy, a promising approach for treating persistent infections. Key developments include positive Phase 2 data for BX211 in treating _S. aureus_ infections, demonstrating sustained ulcer reduction and superior recovery outcomes in bone-depth ulcers. Additionally, BX004 has shown positive Phase 1b/2a results in cystic fibrosis patients with _P. aeruginosa_ infections, indicating sputum culture conversion, improved lung function, and bacterial reduction, with an ongoing Phase 2b study. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。